Phaseline

Companies › GIE Medical

GIE Medical: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GIE Medical ProTractX3 TTS DCB
Paclitaxel-coated balloon catheter
TubulinPhase 3Bowel; Stricture; Esophageal StrictureDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05561127GIE Medical ProTractX3 TTS DCBPhase 3Bowel; StrictureGastroenterologyDec 2027
NCT05561114GIE Medical ProTractX3 TTS DCBPhase 3Esophageal StrictureGastroenterologyApr 2031

Targets

Tubulin (1)

Companies with the same targets

Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Urotronic

Companies built like this

Ostia Sciences Cook MyoSite Myungmoon Pharma. Pharmicell Green Cross Wellbeing

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.